Jon Kayyem - GenMark Diagnostics Founder and Sr. VP of RandD
Founder
Dr. Jon Faiz Kayyem, Ph.D., is serving as Senior Vice President Research and Development of GenMark Diagnostics Inc. Jon Faiz Kayyem, Ph.D. has served as Senior Vice President, Research and Development since June 2013. Dr. Kayyem previously served as the Companys Chief Scientific Officer from August 2010 to June 2013. Dr. Kayyem served as President and Chief Executive Officer of the Company from May 2010 to August 2010. From August 2009 to May 2010, Dr. Kayyem served as President and Chief Executive Officer of Osmetech plc and Chairman of the board of directors of Osmetech plc from January 2009 to August 2009. Dr. Kayyem attended Yale University and received a combined M.S. and B.S. in Molecular Biophysics and Biochemistry in 1985. Dr. Kayyem received his Ph.D. in Molecular Biology in 1991 from The California Institute of Technology since 2013.
| Age | 52 |
| Tenure | 11 years |
| Professional Marks | Ph.D |
| Phone | 760 448-4300 |
| Web | www.genmarkdx.com |
GenMark Diagnostics Management Efficiency
The company has return on total asset (ROA) of (2.63) % which means that it has lost $2.63 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.06) %, meaning that it created substantial loss on money invested by shareholders. GenMark Diagnostics' management efficiency ratios could be used to measure how well GenMark Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 87.14 M in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. GenMark Diagnostics has a current ratio of 3.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist GenMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, GenMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GenMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GenMark to invest in growth at high rates of return. When we think about GenMark Diagnostics' use of debt, we should always consider it together with cash and equity.
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. The company was incorporated in 2010 and is headquartered in Carlsbad, California. Genmark Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 618 people. GenMark Diagnostics (GNMK) is traded on NASDAQ Exchange in USA and employs 618 people. Management Performance
| Return On Equity | -35.06 | |||
| Return On Asset | -2.63 |
GenMark Diagnostics Leadership Team
Elected by the shareholders, the GenMark Diagnostics' board of directors comprises two types of representatives: GenMark Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GenMark. The board's role is to monitor GenMark Diagnostics' management team and ensure that shareholders' interests are well served. GenMark Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GenMark Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James McNally, Senior Vice President Marketing and Business Development | ||
| Michael Gleeson, Sr. VP of North American Commercial Operations | ||
| Brian Mitchell, Senior Vice President Operations | ||
| Kevin OBoyle, Independent Director | ||
| Jennifer Williams, Sr. VP of HR | ||
| Scott Mendel, CFO | ||
| Ingo Chakravarty, Sr. VP of International | ||
| James Fox, Independent Director | ||
| Jon Kayyem, Founder and Sr. VP of RandD | ||
| Eric Stier, Senior Vice President General Counsel, Secretary | ||
| Michael Kagnoff, Director | ||
| Hany Massarany, CEO and President and Director | ||
| Lisa Giles, Director | ||
| Daryl Faulkner, Independent Director | ||
| Johnny Ek, CFO |
GenMark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GenMark Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.06 | |||
| Return On Asset | -2.63 | |||
| Profit Margin | (10.87) % | |||
| Operating Margin | (4.11) % | |||
| Current Valuation | 1.71 B | |||
| Shares Outstanding | 73.59 M | |||
| Shares Owned By Insiders | 4.72 % | |||
| Shares Owned By Institutions | 95.28 % | |||
| Number Of Shares Shorted | 5.56 M | |||
| Price To Earning | (6.42) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GenMark Diagnostics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GenMark Diagnostics' short interest history, or implied volatility extrapolated from GenMark Diagnostics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in GenMark Stock
If you are still planning to invest in GenMark Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GenMark Diagnostics' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |